Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids

M. Rossmeisl, ZM. Jilkova, O. Kuda, T. Jelenik, D. Medrikova, B. Stankova, B. Kristinsson, GG. Haraldsson, H. Svensen, I. Stoknes, P. Sjövall, Y. Magnusson, MG. Balvers, KC. Verhoeckx, E. Tvrzicka, M. Bryhn, J. Kopecky,

. 2012 ; 7 (6) : e38834.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13000725

Grantová podpora
NS10528 MZ0 CEP - Centrální evidence projektů

BACKGROUND: n-3 polyunsaturated fatty acids, namely docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduce the risk of cardiovascular disease and can ameliorate many of obesity-associated disorders. We hypothesised that the latter effect will be more pronounced when DHA/EPA is supplemented as phospholipids rather than as triglycerides. METHODOLOGY/PRINCIPAL FINDINGS: In a 'prevention study', C57BL/6J mice were fed for 9 weeks on either a corn oil-based high-fat obesogenic diet (cHF; lipids ∼35% wt/wt), or cHF-based diets in which corn oil was partially replaced by DHA/EPA, admixed either as phospholipids or triglycerides from marine fish. The reversal of obesity was studied in mice subjected to the preceding cHF-feeding for 4 months. DHA/EPA administered as phospholipids prevented glucose intolerance and tended to reduce obesity better than triglycerides. Lipemia and hepatosteatosis were suppressed more in response to dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver, white adipose tissue (WAT), and muscle phospholipids. In dietary obese mice, both DHA/EPA concentrates prevented a further weight gain, reduced plasma lipid levels to a similar extent, and tended to improve glucose tolerance. Importantly, only the phospholipid form reduced plasma insulin and adipocyte hypertrophy, while being more effective in reducing hepatic steatosis and low-grade inflammation of WAT. These beneficial effects were correlated with changes of endocannabinoid metabolome in WAT, where phospholipids reduced 2-arachidonoylglycerol, and were more effective in increasing anti-inflammatory lipids such as N-docosahexaenoylethanolamine. CONCLUSIONS/SIGNIFICANCE: Compared with triglycerides, dietary DHA/EPA administered as phospholipids are superior in preserving a healthy metabolic profile under obesogenic conditions, possibly reflecting better bioavalability and improved modulation of the endocannabinoid system activity in WAT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13000725
003      
CZ-PrNML
005      
20141022100408.0
007      
ta
008      
130108s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0038834 $2 doi
035    __
$a (PubMed)22701720
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rossmeisl, Martin $u Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of the Czech Republic v.v.i., Prague, Czech Republic.
245    10
$a Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids / $c M. Rossmeisl, ZM. Jilkova, O. Kuda, T. Jelenik, D. Medrikova, B. Stankova, B. Kristinsson, GG. Haraldsson, H. Svensen, I. Stoknes, P. Sjövall, Y. Magnusson, MG. Balvers, KC. Verhoeckx, E. Tvrzicka, M. Bryhn, J. Kopecky,
520    9_
$a BACKGROUND: n-3 polyunsaturated fatty acids, namely docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduce the risk of cardiovascular disease and can ameliorate many of obesity-associated disorders. We hypothesised that the latter effect will be more pronounced when DHA/EPA is supplemented as phospholipids rather than as triglycerides. METHODOLOGY/PRINCIPAL FINDINGS: In a 'prevention study', C57BL/6J mice were fed for 9 weeks on either a corn oil-based high-fat obesogenic diet (cHF; lipids ∼35% wt/wt), or cHF-based diets in which corn oil was partially replaced by DHA/EPA, admixed either as phospholipids or triglycerides from marine fish. The reversal of obesity was studied in mice subjected to the preceding cHF-feeding for 4 months. DHA/EPA administered as phospholipids prevented glucose intolerance and tended to reduce obesity better than triglycerides. Lipemia and hepatosteatosis were suppressed more in response to dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver, white adipose tissue (WAT), and muscle phospholipids. In dietary obese mice, both DHA/EPA concentrates prevented a further weight gain, reduced plasma lipid levels to a similar extent, and tended to improve glucose tolerance. Importantly, only the phospholipid form reduced plasma insulin and adipocyte hypertrophy, while being more effective in reducing hepatic steatosis and low-grade inflammation of WAT. These beneficial effects were correlated with changes of endocannabinoid metabolome in WAT, where phospholipids reduced 2-arachidonoylglycerol, and were more effective in increasing anti-inflammatory lipids such as N-docosahexaenoylethanolamine. CONCLUSIONS/SIGNIFICANCE: Compared with triglycerides, dietary DHA/EPA administered as phospholipids are superior in preserving a healthy metabolic profile under obesogenic conditions, possibly reflecting better bioavalability and improved modulation of the endocannabinoid system activity in WAT.
650    _2
$a bílá tuková tkáň $x metabolismus $7 D052436
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a zvířata $7 D000818
650    _2
$a biologická dostupnost $7 D001682
650    _2
$a tělesná hmotnost $7 D001835
650    _2
$a modulátory kanabinoidních receptorů $x metabolismus $7 D063385
650    _2
$a dieta s vysokým obsahem tuků $7 D059305
650    _2
$a kyseliny dokosahexaenové $x metabolismus $7 D004281
650    _2
$a kyselina eikosapentaenová $x metabolismus $7 D015118
650    _2
$a endokanabinoidy $7 D063388
650    _2
$a omega-3 mastné kyseliny $x aplikace a dávkování $x metabolismus $x farmakologie $7 D015525
650    _2
$a imunohistochemie $7 D007150
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolomika $7 D055432
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a mikroskopie $7 D008853
650    _2
$a kosterní svaly $x metabolismus $7 D018482
650    _2
$a obezita $x dietoterapie $x prevence a kontrola $7 D009765
650    _2
$a fosfolipidy $x metabolismus $7 D010743
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a triglyceridy $x metabolismus $7 D014280
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jilkova, Zuzana Macek
700    1_
$a Kuda, Ondrej
700    1_
$a Jelenik, Tomas
700    1_
$a Medrikova, Dasa
700    1_
$a Stankova, Barbora
700    1_
$a Kristinsson, Björn
700    1_
$a Haraldsson, Gudmundur G
700    1_
$a Svensen, Harald
700    1_
$a Stoknes, Iren
700    1_
$a Sjövall, Peter
700    1_
$a Magnusson, Ylva
700    1_
$a Balvers, Michiel G J
700    1_
$a Verhoeckx, Kitty C M
700    1_
$a Tvrzicka, Eva
700    1_
$a Bryhn, Morten
700    1_
$a Kopecky, Jan
773    0_
$w MED00180950 $t PLoS ONE $x 1932-6203 $g Roč. 7, č. 6 (2012), s. e38834
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22701720 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130108 $b ABA008
991    __
$a 20141022100406 $b ABA008
999    __
$a ok $b bmc $g 963507 $s 798889
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 7 $c 6 $d e38834 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NS10528 $p MZ0
LZP    __
$a Pubmed-20130108

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...